Skip to main content

Evidence to Improve Care

Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure

Draft Recommendation

  • The Quality business unit at Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends publicly funding natriuretic peptide (BNP or NT-proBNP) testing for the diagnosis of people with suspected heart failure in the community and emergency department settings 

Read the draft recommendation report

Thank you for your comments.

The public feedback period for this topic has ended. All comments will be considered before a final recommendation is made and posted here.

Use the tabs below to learn more about this topic and download supporting draft documents, including the full assessment report.

To be notified once a final recommendation is posted here, sign up for our newsletter.

Heart failure is a major cause of illness and death. About 50,000 Canadians are diagnosed with heart failure each year, and an estimated 600,000 Canadians are living with heart failure. It is important that heart failure be diagnosed early and treated appropriately.

There is no single diagnostic test for heart failure, and diagnosis can be challenging since the symptoms of heart failure can be caused by other conditions. The levels of certain hormones—B-type natriuretic peptide and N-terminal proBNP—in the blood may indicate that a person is experiencing heart failure. Test kits have been developed that can measure the levels of these hormones and possibly help health care practitioners make the diagnosis of heart failure.

This health technology assessment looked at the effectiveness and cost-effectiveness of these test kits. It also looked at the budget impact of publicly funding these tests for adults who might have heart failure. And it looked at the experiences, preferences, and values of people with suspected heart failure.

Read the full health technology assessment report for more information.

Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment (PDF)
February 2021

Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.


Sign up for our newsletter to receive monthly notifications of when draft recommendations are open for feedback

A senior couple looking at their tablet together

Let’s make our health system healthier

Join Our Patient, Family and Public Advisors Program

Patients, families and the public are central to improving health quality.

Man smiling

Sign up for our newsletter

Are you passionate about quality health care for all Ontarians? Stay in-the-know about our newest programs, reports and news.

Health Quality Connect - Health Quality Ontario's newsletter - on an iPad and a cell phone